This is the authors' abstract. We don't add key points for this paper.
Alzheimer’s disease (AD) has a complex pathogenesis in which superoxide anion (O 2 •– ), a key reactive oxygen species (ROS), plays a critical role. Monitoring O 2 •– is essential for understanding AD mechanisms and improving early diagnosis. Chemiluminescence imaging provides high contrast without external excitation, making it ideal for in vivo O 2 •– detection. However, few probes can specifically image O 2 •– in the AD brain. To address this, we designed a chemiluminescence probe, DIP-O, for in vivo O 2 •– imaging in AD. In vitro tests showed that DIP-O emits in the near-infrared region (708 nm) with a tissue penetration depth over 2.0 cm, high sensitivity (LOD = 27.9 nM), and excellent specificity for O 2 •– . We validated its imaging performance in peripheral inflammation models (e.g., arthritis and peritonitis), where it enabled real-time, high-contrast tracking of O 2 •– . Furthermore, DIP-O successfully crossed the blood–brain barrier and distinguished O 2 •– levels in the brains of three-month-old AD mice versus wild-type mice, indicating early diagnostic potential. Finally, we applied DIP-O to monitor age-dependent O 2 •– changes in AD mice, demonstrating its capability for sensitive imaging throughout disease progression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: